Cipla's oncology drug Abraxane will be launched from its Goa facility while respiratory drug Advair will be rolled out from ...

Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by ...

Jefferies analyst Alok Dalal increased the price target for Cipla (NSE:CIPL) Ltd. (CIPLA:IN) shares to INR1,580, up from INR1,560, while maintaining a Hold rating on the stock. The adjustment follows ...

The company reported a 48% year-on-year (y-o-y) jump in its consolidated net profit to ₹1,571 crore in October-December, ...

Preview: India's third largest pharmaceutical company, Cipla, is scheduled to deliver its October-December quarterly earnings ...

Laurus Labs slumped 11.6%, Aurobindo declined 2%, Cipla fell 1.1% and Strides dropped 5%. Other pharma shares also declined ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Mumbai: Cipla has announced that the United States Food and Drugs Administration (USFDA) has concluded an inspection at the ...

Cipla is confident of surpassing its FY25 guidance, with supply challenges for Lanreotide expected to ease by Q1FY26. The ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.